Clinical Trial Update: A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

A Phase 2 single-arm exploratory trial assessing the combination of transarterial chemoembolization with iparomlimab, tuvonralimab, and bevacizumab for unresect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Hepatocellular Carcinoma (HCC), Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING